tirzepatide health canada approval Zepbound approved in for obesity and sleep apnea treatment FDA Grants Tirzepatide a New

Patients with type 2 diabetes face particular risks when combining alcohol with glucose-lowering medications, including hypoglycemia and impaired counter-regulatory responses

Every batch is independently tested by a third-party Canadian laboratory using HPLC and mass spectrometry, with verifiable Certificates of Analysis available for every batch

Weight loss of just 5-10% has been shown to improve insulin sensitivity, reduce androgen levels, restore ovulatory cycles, and enhance fertility in women with PCOS

For weight management under the Zepbound brand, qualification generally requires a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol

Once glucose normalizes, patients should consume a small snack containing protein and complex carbohydrates to prevent recurrence